NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Sees Significant Growth in Short Interest

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) saw a significant growth in short interest in February. As of February 13th, there was short interest totaling 206,623 shares, a growth of 169.4% from the January 29th total of 76,711 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 201,898 shares, the short-interest ratio is currently 1.0 days. Based on an average daily volume of 201,898 shares, the short-interest ratio is currently 1.0 days. Approximately 0.4% of the company’s stock are short sold.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Wall Street Zen raised NeuroOne Medical Technologies to a “sell” rating in a research report on Saturday, February 21st. Zacks Research raised NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $2.23.

Institutional Trading of NeuroOne Medical Technologies

Several large investors have recently added to or reduced their stakes in NMTC. Focus Financial Network Inc. bought a new position in shares of NeuroOne Medical Technologies during the 3rd quarter valued at $31,000. Warberg Asset Management LLC bought a new stake in NeuroOne Medical Technologies in the second quarter worth $27,000. Legato Capital Management LLC acquired a new position in NeuroOne Medical Technologies during the fourth quarter worth $34,000. Squarepoint Ops LLC bought a new position in NeuroOne Medical Technologies during the fourth quarter valued at about $36,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of NeuroOne Medical Technologies in the third quarter worth about $47,000. 16.07% of the stock is owned by institutional investors.

NeuroOne Medical Technologies Trading Up 0.1%

NMTC opened at $0.69 on Friday. The stock has a fifty day moving average price of $0.81 and a 200 day moving average price of $0.80. NeuroOne Medical Technologies has a 1 year low of $0.40 and a 1 year high of $1.16. The stock has a market cap of $34.89 million, a price-to-earnings ratio of -4.06 and a beta of 0.71.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its quarterly earnings results on Tuesday, February 17th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. The company had revenue of $2.89 million during the quarter, compared to the consensus estimate of $2.47 million. NeuroOne Medical Technologies had a negative return on equity of 119.92% and a negative net margin of 78.34%.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.